{"classes":[{"categories":[{"measurements":[{"comment":"Confidence interval could not be calculated as there were no responders","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"0"},{"comment":"Confidence interval could not be calculated as there were no responders","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"0"},{"comment":"Confidence interval could not be calculated as there were no responders","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"0"},{"comment":"Confidence interval could not be calculated as there were no responders","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"0"},{"comment":"Confidence interval could not be calculated as there were no responders","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"0"},{"comment":"Confidence interval could not be calculated as there were no responders","groupId":"OG005","lowerLimit":"NA","upperLimit":"NA","value":"0"},{"comment":"Confidence interval could not be calculated as there were no responders","groupId":"OG006","lowerLimit":"NA","upperLimit":"NA","value":"2"},{"comment":"Confidence interval could not be calculated as there were no responders","groupId":"OG007","lowerLimit":"NA","upperLimit":"NA","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"32"},{"groupId":"OG007","value":"9"}],"units":"Participants"}],"description":"PSA 50 response rate is defined as the response rate that a PSA reduction from Baseline \\>=50% is observed at 12 weeks and beyond (must be confirmed by a second value). The number of participants with PSA \\>=50% reduction is presented along with 95% confidence intervals.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were administered once daily (QD) oral dose of 2 milligrams (mg) GSK525762.","id":"OG000","title":"Part 1: GSK525762 2 mg QD"},{"description":"Participants were administered once daily oral dose of 4 mg GSK525762.","id":"OG001","title":"Part 1: GSK525762 4 mg QD"},{"description":"Participants were administered once daily oral dose of 8 mg GSK525762.","id":"OG002","title":"Part 1: GSK525762 8 mg QD"},{"description":"Participants were administered once daily oral dose of 16 mg GSK525762.","id":"OG003","title":"Part 1: GSK525762 16 mg QD"},{"description":"Participants were administered once daily oral dose of 30 mg GSK525762.","id":"OG004","title":"Part 1: GSK525762 30 mg QD"},{"description":"Participants were administered once daily oral dose of 60 mg GSK525762.","id":"OG005","title":"Part 1: GSK525762 60 mg QD"},{"description":"Participants were administered once daily oral dose of 80 mg GSK525762.","id":"OG006","title":"Part 1: GSK525762 80 mg QD"},{"description":"Participants were administered once daily oral dose of 100 mg GSK525762.","id":"OG007","title":"Part 1: GSK525762 100 mg QD"}],"paramType":"NUMBER","populationDescription":"All Treated Population","reportingStatus":"POSTED","timeFrame":"Median of 1.38 months of drug exposure","title":"Number of Participants With Prostate Specific Antigen (PSA)50 Response-Part 1 QD","type":"PRIMARY","unitOfMeasure":"Participants"}